Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684553 | 1.00 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CACHE | |
| SCHEMBL28303958 | 0.85 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CACHE | |
| SCHEMBL19667668 | 0.80 | DRD2 (0.45) | — | |
| SCHEMBL19711062 | 0.80 | PNMT (0.41) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL19711042 | 0.80 | PNMT (0.41) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL19453936 | 0.80 | DRD2 (0.45) | — | |
| SCHEMBL30207819 | 0.80 | DRD2 (0.45) | — | |
| SCHEMBL19678827 | 0.77 | PNMT (0.39) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL19678825 | 0.77 | PNMT (0.39) | PNMTADRA2AADRA2BADRA2CHTR2C | |
| SCHEMBL23735275 | 0.76 | PNMT (0.60) | PNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PNMT 2003/4885ADRA2A 3923/4885ADRA2B 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.